Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease by Antonio Petrarca, Luigi.

Slides:



Advertisements
Similar presentations
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Advertisements

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.
Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study by Franco Dammacco,
How I treat enteropathy-associated T-cell lymphoma by Antonio Di Sabatino, Federico Biagi, Paolo G. Gobbi, and Gino R. Corazza Blood Volume 119(11):
Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Hierarchical clustering of DEGs in Shp−/− mice, chronic hepatitis C cirrhosis, and NASH. A: unsupervised hierarchical clustering of genes common to the.
The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection by.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis by Paolo Prandoni,
Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration.
by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa
Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.
by James O. Armitage, and Dan L. Longo
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Hepatitis C in the rituximab era
Expression of Cell-Homologous Genes of Human Herpesvirus-8 in Human Immunodeficiency Virus-Negative Lymphoproliferative Diseases by Mario Luppi, Patrizia.
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
How I treat elderly patients with myeloma
Nonmyeloablative conditioning for relapsed follicular lymphoma
Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia by Alida Dominietto, Sarah Pozzi, Maurizio Miglino, Flavio Albarracin,
Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma by Chan Yoon Cheah, Loretta J. Nastoupil,
Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease by Caterina P. Minniti, Caroline Cantilena,
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Pregnancy outcomes after maternal exposure to rituximab
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
An Unusual Cause of Abdominal Pain in Sickle Cell Disease
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.
by Alexander Röth, Andreas Hüttmann, Russell P
Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias by David Gómez-Almaguer, Manuel Solano-Genesta,
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study by Dirk.
by Sabah Sallah, and Jim Y. Wan
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL)‏ by Paolo Strati, Michael J. Keating,
by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases by Massimo Federico, Umberto Vitolo, Pier Luigi Zinzani,
Stage C or not stage C…? by Claire Dearden Blood
CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Has MRD monitoring superseded other prognostic factors in adult ALL?
Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.
Hepatitis C and Lymphoproliferative Disorders: From Mixed Cryoglobulinemia to Non- Hodgkin's Lymphoma  Lenna A. Martyak, Melina Yeganeh, Sammy Saab  Clinical.
Volume 31, Issue 6, (December 1999)
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.
Hepatitis C Virus Infection in the Older Patient
Acute hepatitis C: Current status and remaining challenges
Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia by Francesco.
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.
by Wendy Lim, Sara K. Vesely, and James N. George
A, Transverse T2-weighted fast FLAIR images obtained in a patient with liver cirrhosis during an episode of hepatic encephalopathy. A, Transverse T2-weighted.
Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.
Rituximab immunotherapy: it’s getting personal
by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio
Initial treatment of CLL: integrating biology and functional status
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Optimizing therapy for nodal marginal zone lymphoma
Balancing bleeding in brain metastases
Cold agglutinin disease
Presentation transcript:

Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease by Antonio Petrarca, Luigi Rigacci, Patrizio Caini, Stefano Colagrande, Paolo Romagnoli, Francesco Vizzutti, Umberto Arena, Carlo Giannini, Monica Monti, Paolo Montalto, Marco Matucci-Cerinic, Alberto Bosi, Giacomo Laffi, and Anna Linda Zignego Blood Volume 116(3): July 22, 2010 ©2010 by American Society of Hematology

Behavior of mean values of the main immunologic data of the 19 patients with MC before RTX therapy and at the end of follow-up (six months after therapy interruption). Antonio Petrarca et al. Blood 2010;116: ©2010 by American Society of Hematology

Pattern of HCV RNA, alanine aminotransferase, and CD19 mean values of the 19 patients with HCV-positive MC during the study. Antonio Petrarca et al. Blood 2010;116: ©2010 by American Society of Hematology

Modifications of pretreatment therapeutic measures and ascites severity in the 6 patients with MC and decompensated cirrhosis. Antonio Petrarca et al. Blood 2010;116: ©2010 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.